Education and Events

WHAT IS ELIGIBLE FOR SUBMISSION? 

• Abstract submissions must be an original contribution and not have previously been published or presented at any national/international meeting(s) in the same format at the time of abstract submission.   
• Abstracts describing original research, clinical trials, or case studies/series related to the area of endocrinology may be submitted. 
• By submitting your abstract, you agree to present the abstract if it is selected for presentation during the Annual Meeting.  
• Authors will be requested to sign Copyright Transfer, which transfers to AACE the copyright and all other rights of the material comprising the abstract upon acceptance. Authors will not be permitted to submit copyrighted abstracts to other national/international meeting(s). See Copyright Transfer Agreement for more information.
• If the abstract reports on the results of a clinical trial not yet approved by a regulatory agency, you will be required to identify the trial phase. 
• Clinical trial abstracts should include the trial phase, registration number when applicable, study design, population, intervention or exposure, comparator, primary endpoint, and key safety findings. Research involving human participants, animals, or identifiable patient information must comply with applicable institutional review board, ethics committee, privacy, and consent requirements. Abstracts may be declined if required ethical approvals, consent, or trial registration information is missing or inconsistent with the submitted work.
• Authorship of multiple abstracts is permitted. 

By submitting an abstract, authors affirm that the work is accurate, original, and prepared with appropriate human authorship and oversight. Abstracts must not contain fabricated data, manipulated results, plagiarism, undisclosed duplicate publication, or inappropriate image, text, or data generation. Artificial intelligence tools may not be listed as authors. If such tools are used to assist with writing, editing, translation, analysis, or figure preparation, the submitting author remains responsible for the accuracy, originality, confidentiality, and integrity of the submitted work.

WHAT IS NOT ELIGIBLE FOR SUBMISSION? 

• The same study should not be submitted as multiple abstracts with overlapping content. Abstracts that represent different versions of a single analysis will be rejected. However, it is acceptable to submit multiple abstracts derived from the same study if they address distinct research aims or hypotheses.
• For example, randomized trials often include multiple pre-specified outcomes. In such cases, it is appropriate to submit separate abstracts focusing on different outcomes or endpoints, provided each abstract represents a clearly differentiated analysis.
• Abstracts previously published or presented at any national/international meeting are NOT eligible submissions. 

All abstracts must be submitted using the online submission site at: https://www.abstractscorecard.com/cfp/submit/loginSSO.asp?EventKey=TCKWWRYN.

Abstract Categories

• Adrenal Disorders 
• Diabetes/Prediabetes/Hypoglycemia
• Education/Quality Improvement  
• Lipids/Cardiovascular Health 
• Obesity/Nutrition 
• Parathyroid/Bone Disorders
• Pediatric Endocrinology 
• Pituitary Disorders/Neuroendocrinology 
• Reproductive & Transgender Endocrinology 
• Thyroid  
• Endocrine Disorders in Pregnancy  
• Others (genetic syndromes, new innovation, etc.)

CONTENT

• Prior to submitting the abstract, please ensure that it is proofread by an individual who speaks fluent English and can make recommendations as needed. 
• Preliminary, incomplete, or pending data are not allowed. Abstracts must include final or sufficiently mature results that support the stated conclusion.
• Do not use new technical words, laboratory slang, words not defined in dictionaries, abbreviations, or terminology not consistent with internationally accepted guidelines.
• Define any abbreviations the first time they are used. Omit all names and geographical references in the body of the abstract.
• Organize content as follows: 

• Titles should be brief, clearly indicating the topic category (limited to 250 characters). 
• Trial group names should not appear in the title. 
• Enter the title in the “title” field only and do not enter the title in the body of the abstract.
• Author names and affiliations should not appear in the title. 

Correct example: Long-Term Outcomes After Adrenal-Sparing Surgery in Pediatric Patients with Bilateral Pheochromocytoma

The abstract limit is 3,300 characters. The count excludes the title and author/co-author’s information.

Original Research/Clinical Trial

• Objective: Background or Statement of Purpose – 400 characters
• Methods: Methods, materials, and analytical procedures used – 600 characters
• Results: Summary of the results in sufficient detail to support conclusion – 1,400 characters
• Discussion / Conclusion: Discuss the content and interpret the data – 900 characters

Results should include sufficient quantitative detail to support the conclusion, including sample size, relevant effect estimates, measures of variability or precision, and statistical significance when applicable. Abstracts should avoid vague statements such as “results will be presented” or “data are pending.” Conclusions must be supported by the results included in the abstract.

Case Study/Case Series

• Introduction: 400 characters
• Case description: 2000 characters
• Discussion / Conclusion: 900 characters

When laboratory values are included, authors should provide units of measurement and reference ranges when needed for interpretation. Use internationally recognized terminology and standard units whenever possible.

Use standard abbreviations. Place abbreviations in parentheses after the first time the full word appears. Do not abbreviate compounds in the title of the abstract. Use numerals to indicate numbers, except when beginning sentences. 

AACE will only publish commonly used acronyms included in the unified list of acronyms approved by the principal journal editors in the field of endocrinology. Please refrain from using all trial group acronyms in abstract titles. Acronyms may remain in the body of the abstract and in the author list. 

Tables, images, and/or graphs SHOULD NOT be submitted.  

• Submitting authors will be the main contact for all correspondence during the submission process. NO EXCEPTIONS.   
• The submitting author MUST also be the primary author.
• Do not list authors or commercial relationships in the body of the abstract.
• Please consult with your co-authors on how they would like their names to appear prior to the submission of the abstract. We cannot make author changes after the December 1, 2026 submission deadline. Additionally, no edits or additions can be made to author names after abstract publication. The order in which authors are added to the submission is the same order they will be in the publication, if accepted. Authors need to check prior to submission.
• There is a limit of 15 authors that may be included in the author block. 
• The primary/submitting author will be required to enter all co-author information (names, degrees, institutions) and their declaration(s) of interest. It’s important they gather and confirm that information is correct before submitting an abstract.
• Authorship:
  • The following information needs to be included for each author listed for an abstract:
  • First name
  • Last name
  • Email address
  • Credentials
  • Institution
  • Declaration(s) of Interest

NOTE: Changes to authorship will not be accepted after abstract submissions close on December 1, 2026. Please make sure all authors are included and listed correctly.

All authors must disclose relevant financial relationships, commercial support, and other declarations of interest through the submission system. Disclosures and sources of support should not be included in the abstract body. Abstracts must present data in a balanced, objective, and non-promotional manner. Product names should be avoided unless necessary for scientific clarity, and medications or devices should be identified by generic or nonproprietary names whenever possible.

AACE is committed to independent, objective, and balanced scientific programming. In accordance with accredited continuing medical education standards, authors must declare any discussion of a medical device, drug, biologic, or other medical product that is investigational, unapproved, not regulated or approved by a recognized health authority, or being evaluated or discussed for an unapproved, experimental, or off-label clinical indication.

If the abstract includes investigational, unapproved, or off-label product use, the submitting author must include this information when prompted during abstract submission. The author will be prompted to select whether the product is an investigational product, not approved by a recognized health authority, used for research or clinical trial setting, or used outside approved labeling. If abstract is selected for oral presentation, presenter must include disclosure on slide immediately following the title slide.

AACE recognizes that generative AI and AI-assisted technologies may help authors organize content, improve readability, or survey the literature; however, these tools must not replace the authors’ own critical thinking, expertise, interpretation, or accountability.

Authors must apply AI outputs under direct human oversight; verify the accuracy, completeness, neutrality, and attribution of any AI-generated text or references; and thoroughly edit and adapt AI-generated material so the final abstract reflects the authors’ original ideas, interpretation, and analysis. Authors are also responsible for complying with the terms of service of any AI tool and safeguarding data privacy, intellectual property, and any patient or third-party rights.

All abstracts prepared with substantive assistance from AI tools will be prompted to disclose this information during the submission process. “Substantive assistance” includes language editing, rephrasing or shortening author text; formatting or organizing the abstract; summarizing author notes, data, or source material; literature searching; data analysis or statistical support. Basic grammar or spell-checking by AI does not require disclosure.

AACE does not charge a processing fee for abstract submissions.